{"entity":{"id":"nct03016819","kind":"trial","name":"Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)","aka":["APROMISS"],"tldr":"A phase 3 trial of Anlotinib, Dacarbazine in sarcomas, run by Advenchen Laboratories, LLC, now recruiting.","summary":"Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) is a phase 3 interventional study registered as NCT03016819 by Advenchen Laboratories, LLC, with 325 participants planned, started 2017-08-15 and due to reach its primary completion in 2027-12. Interventions recorded: AL3818, Dacarbazine, AL3818 or placebo, Midazolam 2 mg for CYP3A4 phenotyping, Digoxin (0.25mg). Conditions listed: Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma, Soft-Tissue Sarcoma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03016819","url":"https://clinicaltrials.gov/study/NCT03016819"}],"tags":["ctgov-ingest"],"related":[],"cancers":["sarcoma","alveolar-soft-part-sarcoma","leiomyosarcoma","synovial-sarcoma"],"sections":[],"technologies":["antiangiogenic","kinase-inhibitors"],"targets":[],"drugs":["anlotinib","dacarbazine"],"companies":["advenchen-laboratories"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03016819","phase":"3","setting":"A Phase III Study of AL3818 (Anlotinib, Catequentinib) Hydrochloride Monotherapy in Subjects With Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma","sponsor":"Advenchen Laboratories, LLC","started":"2017-08-15","startedType":"actual","enrolled":325,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03016819/","neighbours":{"cancer":[{"id":"alveolar-soft-part-sarcoma","kind":"cancer","name":"Alveolar soft part sarcoma","route":"/cancers/alveolar-soft-part-sarcoma/"},{"id":"leiomyosarcoma","kind":"cancer","name":"Leiomyosarcoma","route":"/cancers/leiomyosarcoma/"},{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"},{"id":"synovial-sarcoma","kind":"cancer","name":"Synovial sarcoma","route":"/cancers/synovial-sarcoma/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"anlotinib","kind":"drug","name":"Anlotinib","route":"/drugs/anlotinib/"},{"id":"dacarbazine","kind":"drug","name":"Dacarbazine","route":"/drugs/dacarbazine/"}],"company":[{"id":"advenchen-laboratories","kind":"company","name":"Advenchen Laboratories","route":"/companies/advenchen-laboratories/"}]}}